In vitro activity of daptomycin alone and in combination with various antimicrobials against gram-positive cocci

Journal of Chemotherapy

Volumn 18, Issue 1, 2006, Pages 27-32

  Cilli, Feriha ^a   Aydemir, S ^a   Tunger, A ^a  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Antibiotic synergy; Daptomycin; Methicillin resistant staphylococci; Vancomycin resistant enterococci

Indexed keywords

AMPICILLIN; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; DAPTOMYCIN; GENTAMICIN; PIPERACILLIN PLUS TAZOBACTAM; RIFAMPICIN; SULTAMICILLIN; TIMENTIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM IDENTIFICATION; DRUG POTENTIATION; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; GRAM POSITIVE COCCI; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PREVALENCE; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; VANCOMYCIN RESISTANT ENTEROCOCCUS;

EID: 33645099674     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2006.18.1.27     Document Type: Article

References (28)

1. Streit JM, Jones RN, Sader HS. Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organisms. J Antimicrob Chemother 2004; 53: 669-674.
2. Pegues DA. Daptomycin: a viewpoint by David A. Pegues. Drugs 2004; 64(4): 57-58.
3. Safdar N, Andes D, Craig WA. In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother 2004; 48(1): 63-68.
4. Braga PC, Ricci D, Dal Sasso M. Daptomycin morphostructural damage in Bacillus cereus visualized by atomic force microscopy. J Chemother 2002; 14 (4): 336-341.
5. Koneman EW, Allen SD, Janda WM, Schreckenberger PC, Winn WC, eds. Color atlas and textbook of diagnostic microbiology, 5th ed. New York: Lippincott; 1997: 539-650.
6. th informational supplement. NCCLS document M100-S14. Wayne, PA: National Committee for Clinical Laboratory Standards; 2004.
7. Dutka-Malen S, Evers S, Courvalin P. Detection of glycopeptide resistance genotypes and identification to the species level of clinically relevant enterococci by PCR. J Clin Microbiol 1995; 33: 24-27.
8. Eliopoulos GM, Moellering RC. Antimicrobial combinations. In: V. Lorian, ed. Antibiotics in Laboratory Medicine. 4th ed. Baltimore: Williams & Wilkins. 1996: 330-396.
9. White RL, Burgess DS, Manduru M, Bosso JA. Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test. Antimicrob Agents Chemother 1996; 40: 1924-8.
10. Rand KH, Houck H. Synergy of daptomycin with oxacillin and other beta-lactams against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2004; 48 (8): 2871-2875.
11. Arslan H, Azap OK, Ergin F, Karaman SO, Oruc E. In vitro activity of daptomycin against a range of Staphylococcus aureus and Enterococcus isolates: first results from Turkey. Int J Antimicrob Agents 2004; 23 (6): 642-3.
12. Rand KH, Houck H. Daptomycin synergy with rifampicin and ampicillin against vancomycin-resistant enterococci. J Antimicrob Chemother 2004; 53: 530-532.
13. Tedesco KL, Rybak MJ. Daptomycin. Pharmacotherapy 2004; 24(1): 41-57.
14. Jones RN, Barry AL. Antimicrobial activity and spectrum of LY146032, a lipopeptide antibiotic, including susceptibility test recommendations. Antimicrob Agents Chemother 1987; 31: 625-629.
15. Barry AL, Fuchs PC, Brown SD. In vitro activities of daptomycin against 2789 clinical isolates from 11 North American medical centers. Antimicrob Agents Chemother 2001; 45:1919-1922.
16. Wise R, Andrews JM, Ashby JP. Activity of daptomycin against Gram-positive pathogens: a comparison with other agents and the determination of a tentative breakpoint. J Antimicrob Chemother 2001; 48: 563-567.
17. Horgensen JH, Crawford SA, Kelly CC, Patterson JE. In vitro activity of daptomycin against vancomycin-resistant enterococci of various Van types and comparison of susceptibility testing methods. Antimicrob Agents Chemother 2003; 47(12): 3760-3763.
18. Carpenter CF, Chambers HF. Daptomycin: another novel agent for treating infections due to drug-resistant Gram-positive pathogens. Clin Infect Dis 2004; 38: 994-1000.
19. Richter SS, Kealy DE, Murray CT, Heilmann KP, Coffman SL, Doem GV. The in vitro activity of daptomycin against Staphylococcus aureus and Enteroccus species. J Antimicrob Chemother 2003; 52: 123-127.
20. Fluit AC, Schmitz FJ, Verboeh J, Milatovic D. Daptomycin in vitro susceptibility in European Gram-positive clinical isolates. Int J Antimicrob Agents 2004; 24: 59-66.
21. Segreti J. Efficacy of current agents used in the treatment of Gram-positive infections and the consequences of resistance. Clin Microbiol Infect 2005; 11 (3): 29-35.
22. Steenbergen JN, Alder J, Thorne GM, Tally FP. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J Antimicrob Chemother 2005; 55: 283-288.
23. Mangili A, Bica I, Syndman R, Hamer DH. Daptomycin-resistant, methicilin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2005; 40: 1058-1060.
24. Silverman JA, Oliver N, Andrew T, Li T. Resistance studies with daptomycin. Antimicrob Agents Chemother 2001; 45:1799-1802.
25. Bonapace CR, White RL, Friedrich LW, Bosso JA. Evaluation of antibiotic synergy against Acinetobacter baumannii: a comparison with E test, time-kill, and checkerboard methods. Diagn Microbiol Infect Dis 2004; 38: 43-50.
26. Lewis RE, Diekema DJ, Messe SA, Pfaller MA, Klepser ME. Comparison of E test, checkerboard dilution and time-kill studies for the detection of synergy or antagonism between antifungal agents tested against Candida species. J Antimicrob Chemother 2002; 49: 345-351.
27. Kocazeybek BS, Arabaci U, Erenturk S, Akdur, H. Investigation of various antibiotic combinations using the E-test method in multiresistant Pseudomonas aeruginosa. Chemotherapy 2002; 48(1): 31-35.
28. Louie A, Baltch AL, Ritz WJ, Smith RP, Asperilla M. Comparison of in vitro inhibitory and bactericidal activities of daptomycin (LY146032) and four reference antibiotics, singly and in combination, against gentamicin-susceptible and high-level gentamicin-resistant enterococci. Chemotherapy 1993; 39: 302-310.